Tenet Healthcare Corp: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 5, 2018 and accepted by EDGAR at Nov 5, 2018, 16:27 ET.
Management's discussion and analysis
As filed, 130,087 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
INTRODUCTION TO MANAGEMENT’S DISCUSSION AND ANALYSIS
The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), is to provide a narrative explanation of our financial statements that enables investors to better understand our business, to enhance our overall financial disclosures, to provide the context within which our financial information may be analyzed, and to provide information about the quality of, and potential variability of, our financial condition, results of operations and cash flows. Our Hospital Operations and other segment is comprised of our acute care and specialty hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. As described in Note 4 to the accompanying Condensed Consolidated Financial Statements, certain of our facilities were classified as held for sale at September 30, 2018. Our Ambulatory Care segment is comprised of the operations of our USPI Holding Company, Inc. (“USPI”), in which we own a majority interest, and included nine European Surgical Partners Limited (“Aspen”) facilities until their divestiture effective August 17, 2018. At September 30, 2018, USPI had interests in 255 ambulatory surgery centers, 36 urgent care centers, 23 imaging centers and 21 surgical hospitals in 27 states. Our Conifer segment provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities, through our Conifer Holdings, Inc. (“Conifer”) subsidiary. MD&A, which should be read in conjunction with the accompanying Condensed Consolidated Financial Statements, includes the following sections:
- Management Overview
- Forward-Looking Statements
- Sources of Revenue for Our Hospital Operations and Other Segment
- Results of Operations
- Liquidity and Capital Resources
- Off-Balance Sheet Arrangements
- Critical Accounting Estimates
Unless otherwise indicated, all financial and statistical information included in MD&A relates to our continuing operations, with dollar amounts expressed in millions (except per adjusted admission, per adjusted patient day and per case amounts). Continuing operations information includes the results of (i) our same 68 hospitals operated throughout the nine months ended September 30, 2018 and 2017, (ii) three Houston-area hospitals, which we divested effective August 1, 2017, (iii) Abrazo Maryvale Campus, which we closed in December 2017, (iv) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (v) MacNeal Hospital, which we divested effective March 1, 2018, and (vi) Des Peres Hospital, which we divested effective May 1, 2018. The results of our Aspen facilities are included until August 17, 2018, the date of divestiture. Continuing operations information excludes the results of our hospitals and other businesses that have been classified as discontinued operations for accounting purposes. In addition, although we operated four North Texas hospitals throughout the nine months ended September 30, 2017 and from January 1 through February 28, 2018, we did not consolidate the results of operations of these hospitals because we divested a controlling interest in them effective January 1, 2016.
MANAGEMENT OVERVIEW
RECENT DEVELOPMENTS
*Divestiture of Our Aspen Subsidiary—*On August 17, 2018, we completed the previously announced sale of HCN European Surgery Center Holdings Limited, which owns Aspen, for net pre-tax cash proceeds of approximately $15 million. Aspen’s assets in the United Kingdom include nine private hospitals and clinics. The sale is subject to customary post-closing purchase price adjustments. With this transaction, we no longer operate healthcare facilities outside of the United States.
TRENDS AND STRATEGIES
The healthcare industry, in general, and the acute care hospital business, in particular, have been experiencing significant regulatory uncertainty based, in large part, on legislative and administrative efforts to significantly modify or repeal and potentially replace the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (“Affordable Care Act” or “ACA”). Although it is difficult to predict the full impact of this regulatory uncertainty on our future revenues and operations, we believe that our strategies will help us to address the following trends shaping the demand for healthcare services: (1) consumers, employers and insurers are actively seeking lower-cost solutions and better value as they focus more on healthcare spending; (2) patient volumes are shifting from inpatient to outpatient settings due to technological advancements and demand for care that is more convenient, affordable and accessible; (3) the industry is migrating to value-based payment models with government and private payers shifting risk to providers; and (4) consolidation continues across the entire healthcare sector.
*Driving Growth in Our Hospital Systems—*We are committed to better positioning our hospital systems and competing more effectively in the ever-evolving healthcare environment. We are focused on improving operational effectiveness, increasing capital efficiency and margins, enhancing patient satisfaction, growing our higher-acuity inpatient service lines, expanding patient access points, and exiting service lines, businesses and markets that we believe are no longer strategic to our long-term growth. We have undertaken enterprise-wide cost reduction initiatives, comprised primarily of workforce reductions (including streamlining corporate overhead and centralized support functions), the renegotiation of contracts with suppliers and vendors, and the consolidation of office locations, which are intended to lower annual operating expenses by $250 million. We anticipate achieving the full annualized run-rate savings by the end of 2018. Most of the savings are expected to be achieved through actions within both our Hospital Operations and other segment and our Conifer segment. In conjunction with these initiatives, we incurred restructuring charges related to employee severance payments of approximately $47 million in the nine months ended September 30, 2018, and we expect to incur additional such restructuring charges in the remainder of 2018.
*Expansion of Our Ambulatory Care Segment—*We remain focused on opportunities to expand our Ambulatory Care segment through organic growth, building new outpatient centers, corporate development activities and strategic partnerships. We believe USPI’s surgery centers and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience. Moreover, due in part to advancements in medical technology, and due to the lower cost structure and greater efficiencies that are attainable at a specialized outpatient site, we believe the volume and complexity of surgical cases performed in an outpatient setting will continue to steadily increase. In addition, we have continued to grow our imaging and urgent care businesses through USPI to reflect our broader strategies to (1) offer more services to patients, (2) broaden the capabilities we offer to healthcare systems and physicians, and (3) expand into faster-growing, less capital intensive, higher-margin businesses. Historically, our outpatient services have generated significantly higher margins for us than inpatient services.
*Exploration of Strategic Alternatives for Conifer While Continuing to Drive Conifer’s Growth—*We previously announced a number of actions to support our goals of improving financial performance and enhancing shareholder value, including the exploration of a potential sale of Conifer. In addition to a potential sale, we are considering other strategic alternatives for Conifer, such as a merger, a tax efficient spin-off or a combination of alternative transactions. There can be no assurance that this process will result in any transaction.
Conifer serves approximately 780 Tenet and non-Tenet hospital and other clients nationwide. In addition to providing revenue cycle management services to both healthcare systems and physicians, Conifer provides support to both providers and self-insured employers seeking assistance with clinical integration, financial risk management and population health management. Conifer remains focused on driving growth by continuing to market and expand its revenue cycle management and value-based care solutions businesses.
*Improving Profitability—*We are focused on growing patient volumes and effective cost management as a means to improve profitability. We believe our patient volumes have been constrained by increased competition, utilization pressure by managed care organizations, new delivery models that are designed to lower the utilization of acute care hospital services, the effects of higher patient co-pays, co-insurance amounts and deductibles, changing consumer behavior, and adverse economic conditions and demographic trends in certain of our markets. However, we also believe that targeted capital spending on growth opportunities for our hospitals, emphasis on higher-demand clinical service lines (including outpatient services), focus on expanding our ambulatory care business and contracting strategies that create shared value with payers should help us grow our patient volumes over time.
*Reducing Our Leverage—*All of our outstanding long-term debt has a fixed rate of interest, and the maturity dates of our notes are staggered from 2019 through 2031. Although we believe that our capital structure minimizes the near-term impact of increased interest rates, and the staggered maturities of our debt allow us to refinance our debt over time, it is nonetheless our long-term objective to lower our ratio of debt-to-Adjusted EBITDA, primarily through more efficient capital allocation and Adjusted EBITDA growth, which should lower our refinancing risk and increase the potential for us to continue to use lower rate secured debt to refinance portions of our higher rate unsecured debt.
Our ability to execute on our strategies and manage the aforementioned trends is subject to a number of risks and uncertainties that may cause actual results to be materially different from expectations. For information about risks and uncertainties that could affect our results of operations, see the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report on Form 10-K for the year ended December 31, 2017 (“Annual Report”).
RESULTS OF OPERATIONS—OVERVIEW
The following tables show certain selected operating statistics for our continuing operations, which includes the results of (i) our same 68 hospitals operated throughout the nine months ended September 30, 2018 and 2017, (ii) three Houston-area hospitals, which we divested effective August 1, 2017, (iii) Abrazo Maryvale Campus, which we closed in December 2017, (iv) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (v) MacNeal Hospital, which we divested effective March 1, 2018, and (vi) Des Peres Hospital, which we divested effective May 1, 2018. The results of our Aspen facilities are included until August 17, 2018, the date of divestiture. We believe this information is useful to investors because it reflects our current portfolio of operations and the recent trends we are experiencing with respect to volumes, revenues and expenses.
| Selected Operating Statistics Hospital Operations and other – hospitals and related outpatient facilities | Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | |
|---|---|---|---|---|
| Number of hospitals (at end of period) | 68 | 73 | (5) | (1) |
| Total admissions | 168,201 | 185,389 | (9.3)% | |
| Adjusted patient admissions(2) | 306,197 | 332,035 | (7.8)% | |
| Paying admissions (excludes charity and uninsured) | 157,193 | 174,803 | (10.1)% | |
| Charity and uninsured admissions | 11,008 | 10,586 | 4.0% | |
| Emergency department visits | 638,248 | 685,096 | (6.8)% | |
| Total surgeries | 107,094 | 118,260 | (9.4)% | |
| Patient days — total | 761,920 | 853,059 | (10.7)% | |
| Adjusted patient days(2) | 1,365,662 | 1,502,831 | (9.1)% | |
| Average length of stay (days) | 4.53 | 4.60 | (1.5)% | |
| Average licensed beds | 18,302 | 19,783 | (7.5)% | |
| Utilization of licensed beds(3) | 45.3% | 46.9% | (1.6)% | (1) |
| Total visits | 1,722,292 | 1,867,471 | (7.8)% | |
| Paying visits (excludes charity and uninsured) | 1,607,184 | 1,741,815 | (7.7)% | |
| Charity and uninsured visits | 115,108 | 125,656 | (8.4)% | |
| Ambulatory Care | ||||
| Total consolidated facilities (at end of period) | 228 | 220 | 8 | (1) |
| Total cases | 491,377 | 454,484 | 8.1% |
(1) The change is the difference between the 2018 and 2017 amounts shown.
(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.
Total admissions decreased by 17,188, or 9.3%, in the three months ended September 30, 2018 compared to the three months ended September 30, 2017, and total surgeries decreased by 11,166, or 9.4%, in the 2018 period compared to the 2017 period. Our emergency department visits decreased 6.8% in the three months ended September 30, 2018 compared to the same period in the prior year. Our volumes from continuing operations in the three months ended September 30, 2018 compared to the three months ended September 30, 2017 were negatively affected by the closure of our Abrazo Maryvale Campus in December 2017, the sale of our Philadelphia-area facilities effective January 11, 2018, the sale of MacNeal Hospital and affiliated operations effective March 1, 2018, and the sale of Des Peres Hospital and affiliated operations effective May 1, 2018. Our Ambulatory Care total cases increased 8.1% due to the increase in consolidated facilities, as well as increased same-facility volumes.
| Revenues Net operating revenues | Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) |
|---|---|---|---|
| Hospital Operations and other prior to inter-segment eliminations | $3,762 | $3,866 | (2.7)% |
| Ambulatory Care | 502 | 468 | 7.3% |
| Conifer | 371 | 401 | (7.5)% |
| Inter-segment eliminations | (146) | (149) | (2.0)% |
| Total | $4,489 | $4,586 | (2.1)% |
Net operating revenues decreased by $97 million, or 2.1%, in the three months ended September 30, 2018 compared to the same period in 2017, primarily due to the sale and closure of facilities described above. For our Hospital Operations and other segment, the decrease in net operating revenues was partially mitigated by improved managed care pricing. Also, the 2018 period included $71 million of net revenues from the California provider fee program compared to no revenue recorded under this program in the 2017 period because the extension of the program had not yet been approved by the Centers for Medicare and Medicaid Services (“CMS”).
Our accounts receivable days outstanding (“AR Days”) from continuing operations were 56.3 days at September 30, 2018 and 55.8 days at December 31, 2017, compared to our target of less than 55 days. (This calculation includes our Hospital Operations and other contract assets subsequent to the adoption of the Financial Accounting Standards Board Accounting Standards Update 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”) effective January 1, 2018 and the accounts receivable of our Chicago-area facilities that have been classified in assets held for sale on our Condensed Consolidated Balance Sheet at September 30, 2018, and excludes (i) three Houston-area hospitals, which we divested effective August 1, 2017, (ii) Abrazo Maryvale Campus, which we closed in December 2017, (iii) two Philadelphia-area hospitals, which we divested effective January 11, 2018, (iv) MacNeal Hospital, which we divested effective March 1, 2018, (v) Des Peres Hospital, which we divested effective May 1, 2018, (vi) Aspen facilities, which we divested effective August 17, 2018, (vii) health plan revenues, and (viii) our California provider fee revenues.)
| Selected Operating Expenses Hospital Operations and other | Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) |
|---|---|---|---|
| Salaries, wages and benefits | $1,746 | $1,879 | (7.1)% |
| Supplies | 621 | 644 | (3.6)% |
| Other operating expenses | 930 | 936 | (0.6)% |
| Total | $3,297 | $3,459 | (4.7)% |
| Ambulatory Care | |||
| Salaries, wages and benefits | $157 | $155 | 1.3% |
| Supplies | 104 | 95 | 9.5% |
| Other operating expenses | 88 | 93 | (5.4)% |
| Total | $349 | $343 | 1.7% |
| Conifer | |||
| Salaries, wages and benefits | $213 | $230 | (7.4)% |
| Supplies | 1 | 1 | —% |
| Other operating expenses | 76 | 91 | (16.5)% |
| Total | $290 | $322 | (9.9)% |
| Total | |||
| Salaries, wages and benefits | $2,116 | $2,264 | (6.5)% |
| Supplies | 726 | 740 | (1.9)% |
| Other operating expenses | 1,094 | 1,120 | (2.3)% |
| Total | $3,936 | $4,124 | (4.6)% |
| Rent/lease expense(1) | |||
| Hospital Operations and other | $57 | $61 | (6.6)% |
| Ambulatory Care | 20 | 20 | —% |
| Conifer | 4 | 4 | —% |
| Total | $81 | $85 | (4.7)% |
(1) Included in other operating expenses.
| Selected Operating Expenses per Adjusted Patient Admission Hospital Operations and other | Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) |
|---|---|---|---|
| Salaries, wages and benefits per adjusted patient admission(1) | $5,700 | $5,651 | 0.9% |
| Supplies per adjusted patient admission(1) | 2,028 | 1,938 | 4.6% |
| Other operating expenses per adjusted patient admission(1) | 3,043 | 2,778 | 9.5% |
| Total per adjusted patient admission | $10,771 | $10,367 | 3.9% |
(1) Calculation excludes the expenses from our health plan businesses. Adjusted patient admissions represents actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
Salaries, wages and benefits per adjusted patient admission increased 0.9% in the three months ended September 30, 2018 compared to the same period in 2017. This change is primarily due to annual merit increases for certain of our employees and increased health benefits costs, partially offset by the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives and the impact of favorable workers’ compensation experience.
Supplies expense per adjusted patient admission increased 4.6% in the three months ended September 30, 2018 compared to the three months ended September 30, 2017 primarily due to increased costs from certain higher acuity supply-intensive surgical services.
Other operating expenses per adjusted patient admission increased by 9.5% in the three months ended September 30, 2018 compared to the prior-year period. This increase is primarily due to the effect of lower volumes on operating leverage due to certain fixed costs, increased medical fees, including increased medical losses on risk-based capitated contracts in California, increased technology and software costs, and increased malpractice expense to settle various claims. Other operating expenses in the 2018 period were offset by gains on sales of assets of $19 million primarily related to the sale of an equity method investment. In the 2018 period, we recognized a favorable adjustment of approximately $5 million from a 20 basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2017 period, we recognized a favorable adjustment of approximately $1 million from a two basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities.
LIQUIDITY AND CAPITAL RESOURCES OVERVIEW
Cash and cash equivalents were $500 million at September 30, 2018 compared to $403 million at June 30, 2018.
Significant cash flow items in the three months ended September 30, 2018 included:
- Net cash provided by operating activities before interest, taxes, discontinued operations and restructuring charges, acquisition-related costs, and litigation costs and settlements of $543 million;
- Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements of $50 million;
- Capital expenditures of $136 million;
- $8 million of payments for the purchases of businesses or joint venture interests;
- Proceeds from sale of marketable securities, long-term investments and other assets of $22 million;
- Proceeds from the sales of facilities and other assets of $17 million;
- Interest payments of $151 million;
- $36 million of payments to purchase approximately $38 million aggregate principal amount of our 6.875% senior unsecured notes due 2031; and
- $77 million of distributions paid to noncontrolling interests.
Net cash provided by operating activities was $799 million in the nine months ended September 30, 2018 compared to $709 million in the nine months ended September 30, 2017. Key factors contributing to the change between the 2018 and 2017 periods include the following:
- Increased net cash receipts of $152 million related to the California provider fee program;
- Additional interest payments of $35 million in the 2018 period primarily due to the six-month interest payment in January 2018 related to our 7.500% senior secured second lien notes due 2022, which were issued in December 2016; changes in the timing of certain interest payments as a result of our refinancing transactions in 2017 also impacted the year-over-year comparison;
- $25 million of additional payments in the 2018 period for restructuring charges, acquisition-related costs, and litigation costs and settlements;
- Lower income tax payments of $30 million in the 2018 period;
- Increased cash flows from our health plan businesses of approximately $100 million due to cash outflows in the 2017 period resulting from the sales and wind-down of these businesses in 2017, compared to negligible cash flows in the 2018 period; and
- The timing of other working capital items.
FORWARD-LOOKING STATEMENTS
This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements, other than statements of historical or present facts, that address activities, events, outcomes, business strategies and other matters that we plan, expect, intend, assume, believe, budget, predict, forecast, project, target, estimate or anticipate (and other similar expressions) will, should or may occur in the future are forward-looking statements. These forward-looking statements represent management’s current expectations, based on currently available information, as to the outcome and timing of future events. They involve known and unknown risks, uncertainties and other factors — many of which we are unable to predict or control — that may cause our actual results, performance or achievements, or healthcare industry results, to be materially different from those expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risks described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.
When considering forward-looking statements, a reader should keep in mind the risk factors and other cautionary statements in our Annual Report and in this report. Should one or more of the risks and uncertainties described in our Annual Report or this report occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statement. We specifically disclaim any obligation to update any information contained in a forward-looking statement or any forward-looking statement in its entirety and, therefore, disclaim any resulting liability for potentially related damages.
All forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.
SOURCES OF REVENUE FOR OUR HOSPITAL OPERATIONS AND OTHER SEGMENT
We earn revenues for patient services from a variety of sources, primarily managed care payers and the federal Medicare program, as well as state Medicaid programs, indemnity-based health insurance companies and self-pay patients (that is, patients who do not have health insurance and are not covered by some other form of third-party arrangement).
The following table shows the sources of net patient revenues less implicit price concessions and provision for doubtful accounts for our hospitals and related outpatient facilities, expressed as percentages of net patient revenues less implicit price concessions and provision for doubtful accounts from all sources:
| Net Patient Revenues Less Implicit Price Concessions and Provision for Doubtful Accounts from: | Three Months Ended September 30, 2018 | 2017 | Increase (Decrease)(1) | Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease)(1) |
|---|---|---|---|---|---|---|
| Medicare | 19.8% | 22.0% | (2.2)% | 20.6% | 22.4% | (1.8)% |
| Medicaid | 9.8% | 7.1% | 2.7% | 9.2% | 7.4% | 1.8% |
| Managed care(2) | 64.9% | 66.1% | (1.2)% | 65.3% | 65.7% | (0.4)% |
| Self-pay | 0.9% | 0.3% | 0.6% | 0.7% | 0.4% | 0.3% |
| Indemnity and other | 4.6% | 4.5% | 0.1% | 4.2% | 4.1% | 0.1% |
(1) The change is the difference between the 2018 and 2017 percentages shown.
(2) Includes Medicare and Medicaid managed care programs.
Our payer mix on an admissions basis for our hospitals and related outpatient facilities, expressed as a percentage of total admissions from all sources, is shown below:
| Admissions from: | Three Months Ended September 30, 2018 | 2017 | Increase (Decrease)(1) | Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease)(1) |
|---|---|---|---|---|---|---|
| Medicare | 24.4% | 25.1% | (0.7)% | 25.5% | 26.0% | (0.5)% |
| Medicaid | 6.5% | 6.7% | (0.2)% | 6.3% | 6.5% | (0.2)% |
| Managed care(2) | 60.0% | 60.2% | (0.2)% | 59.6% | 59.7% | (0.1)% |
| Self-pay | 6.5% | 5.7% | 0.8% | 6.0% | 5.5% | 0.5% |
| Indemnity and other | 2.6% | 2.3% | 0.3% | 2.6% | 2.3% | 0.3% |
(1) The change is the difference between the 2018 and 2017 percentages shown.
(2) Includes Medicare and Medicaid managed care programs.
GOVERNMENT PROGRAMS
The Centers for Medicare and Medicaid Services, an agency of the U.S. Department of Health and Human Services (“HHS”), is the single largest payer of healthcare services in the United States. Approximately 57 million individuals rely on healthcare benefits through Medicare, and approximately 74 million individuals are enrolled in Medicaid and the Children’s Health Insurance Program (“CHIP”). These three programs are authorized by federal law and administered by CMS. Medicare is a federally funded health insurance program primarily for individuals 65 years of age and older, certain younger people with disabilities, and people with end-stage renal disease, and is provided without regard to income or assets. Medicaid is administered by the states and is jointly funded by the federal government and state governments. Medicaid is the nation’s main public health insurance program for people with low incomes and is the largest source of health coverage in the United States. The CHIP, which is also administered by the states and jointly funded, provides health coverage to children in families with incomes too high to qualify for Medicaid, but too low to afford private coverage. Unlike Medicaid, the CHIP is limited in duration and requires the enactment of reauthorizing legislation. During the three months ended March 31, 2018, separate pieces of legislation were enacted extending CHIP funding for a total of ten years from federal fiscal year (“FFY”) 2018 (which began on October 1, 2017) through FFY 2027.
Medicare
Medicare offers its beneficiaries different ways to obtain their medical benefits. One option, the Original Medicare Plan (which includes “Part A” and “Part B”), is a fee-for-service payment system. The other option, called Medicare Advantage (sometimes called “Part C” or “MA Plans”), includes health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), private fee-for-service Medicare special needs plans and Medicare medical savings account plans. The major components of our net patient revenues from continuing operations of the hospitals and related outpatient facilities in our Hospital Operations and other segment for services provided to patients enrolled in the Original Medicare Plan for the three and nine months ended September 30, 2018 and 2017 are set forth in the following table:
| Revenue Descriptions | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
|---|---|---|---|---|
| Medicare severity-adjusted diagnosis-related group — operating | $355 | $388 | $1,152 | $1,248 |
| Medicare severity-adjusted diagnosis-related group — capital | 32 | 37 | 104 | 115 |
| Outliers | 16 | 21 | 64 | 64 |
| Outpatient | 178 | 184 | 561 | 577 |
| Disproportionate share | 55 | 65 | 169 | 204 |
| Direct Graduate and Indirect Medical Education(1) | 47 | 63 | 150 | 194 |
| Other(2) | (1) | 6 | (38) | 18 |
| Adjustments for prior-year cost reports and related valuation allowances | (1) | 9 | 2 | 35 |
| Total Medicare net patient revenues | $681 | $773 | $2,164 | $2,455 |
(1) Includes Indirect Medical Education revenues earned by our children’s hospitals under the Children’s Hospitals Graduate Medical Education Payment Program administered by the Health Resources and Services Administration of HHS.
(2) The other revenue category includes inpatient psychiatric units, inpatient rehabilitation units, one long-term acute care hospital (which was divested in 2017), other revenue adjustments, and adjustments related to the estimates for current-year cost reports and related valuation allowances.
A general description of the types of payments we receive for services provided to patients enrolled in the Original Medicare Plan is provided in our Annual Report. Recent regulatory and legislative updates to the terms of these payment systems and their estimated effect on our revenues can be found under “Regulatory and Legislative Changes” below.
Medicaid
Medicaid programs and the corresponding reimbursement methodologies are administered by the states and vary from state to state and from year to year. Estimated revenues under various state Medicaid programs, including state-funded managed care Medicaid programs, constituted approximately 19.9% and 19.3% of total net patient revenues less implicit price concessions and provision for doubtful accounts of our hospitals and related outpatient facilities for the nine months ended September 30, 2018 and 2017, respectively. We also receive disproportionate share hospital (“DSH”) and other supplemental revenues under various state Medicaid programs. For the nine months ended September 30, 2018 and 2017, our total Medicaid revenues attributable to DSH and other supplemental revenues were approximately $651 million and $462 million, respectively. The 2018 period included $223 million related the Michigan provider fee program, $198 million from the California provider fee program, $106 million related to Medicaid DSH programs in multiple states, $87 million related to the Texas 1115 waiver program, and $37 million from a number of other state and local programs.
Several states in which we operate face budgetary challenges that have resulted, and likely will continue to result, in reduced Medicaid funding levels to hospitals and other providers. Because most states must operate with balanced budgets, and the Medicaid program is generally a significant portion of a state’s budget, states can be expected to adopt or consider adopting future legislation designed to reduce or not increase their Medicaid expenditures. In addition, some states delay issuing Medicaid payments to providers to manage state expenditures. As an alternative means of funding provider payments, many of the states in which we operate have adopted provider fee programs or received waivers under Section 1115 of the Social Security Act. Under a Medicaid waiver, the federal government waives certain Medicaid requirements, thereby giving states flexibility in the operation of their Medicaid program to allow states to test new approaches and demonstration projects to improve care. Generally the Section 1115 waivers are approved for a period of five years with an option to extend the waiver for three additional years. Continuing pressure on state budgets and other factors could result in future reductions to Medicaid payments, payment delays or additional taxes on hospitals.
Because we cannot predict what actions the federal government or the states may take under existing legislation and future legislation to address budget gaps, deficits, Medicaid expansion, provider fee programs or Medicaid Section 1115 waivers, we are unable to assess the effect that any such legislation might have on our business, but the impact on our future financial position, results of operations or cash flows could be material.
Medicaid-related patient revenues from continuing operations recognized by the hospitals and related outpatient facilities in our Hospital Operations and other segment from Medicaid-related programs in the states in which our facilities are (or were, as the case may be) located, as well as from Medicaid programs in neighboring states, for the nine months ended September 30, 2018 and 2017 are set forth in the following table. These revenues are presented net of provider assessments, which are reported as an offset reduction to fee-for-service Medicaid revenue.
| Hospital Location | Nine Months Ended September 30, 2018 Medicaid | Managed Medicaid | 2017 Medicaid | Managed Medicaid |
|---|---|---|---|---|
| Alabama | $69 | $— | $66 | $— |
| Arizona | (20) | 138 | (3) | 144 |
| California | 329 | 331 | 125 | 320 |
| Florida | 53 | 118 | 52 | 128 |
| Georgia | (1) | 1 | (1) | — |
| Illinois | 35 | 34 | 55 | 53 |
| Massachusetts | 39 | 33 | 24 | 37 |
| Michigan | 316 | 244 | 277 | 258 |
| Missouri | — | — | 1 | 1 |
| Pennsylvania | 2 | 6 | 59 | 156 |
| South Carolina | 15 | 26 | 9 | 25 |
| Tennessee | 3 | 24 | 3 | 23 |
| Texas | 131 | 168 | 140 | 162 |
| $971 | $1,123 | $806 | $1,307 |
Regulatory and Legislative Changes
Material updates to the information set forth in our Annual Report about the Medicare and Medicaid payment systems are provided below.
Payment and Policy Changes to the Medicare Inpatient Prospective Payment Systems
Under Medicare law, CMS is required to annually update certain rules governing the inpatient prospective payment systems (“IPPS”). The updates generally become effective October 1, the beginning of the federal fiscal year. On August 2, 2018, CMS issued Changes to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and Fiscal Year 2019 Rates (“Final IPPS Rule”). The Final IPPS Rule includes the following payment and policy changes:
- A market basket increase of 2.9% for Medicare severity-adjusted diagnosis-related group (“MS-DRG”) operating payments for hospitals reporting specified quality measure data and that are meaningful users of electronic health record (“EHR”) technology (hospitals that do not report specified quality measure data and/or are not meaningful users of EHR technology will receive a reduced market basket increase); CMS also made certain adjustments to the 2.9% market basket increase that result in a net operating payment update of 1.85% (before budget neutrality adjustments), including:
- Market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.8%, respectively; and
- A 0.5% increase required under the 21st Century Cures Act;
- Updates to the three factors used to determine the amount and distribution of Medicare uncompensated care disproportionate share (“UC-DSH”) payments, including the continuation of the transition from using low-income days to estimated uncompensated care costs for the distribution of the UC-DSH amounts;
- A 1.27% net increase in the capital federal MS-DRG rate;
- A decrease in the cost outlier threshold from $26,537 to $25,769;
- The application of the Medicare IPPS post-acute transfer payment policy to “early discharges” from the hospital to hospice care as required by the Bipartisan Budget Act of 2018; and
- Effective January 1, 2019, the requirement that hospitals make available to the public a list of their current standard charges via the Internet in a machine-readable format and update this information at least annually or more often as appropriate.
According to CMS, the combined impact of the payment and policy changes in the Final IPPS Rule for operating costs will yield an average 2.5% increase in Medicare operating MS-DRG fee-for-service (“FFS”) payments for hospitals in large urban areas (populations over one million), and an average 2.1% increase in operating MS-DRG FFS payments for proprietary hospitals in FFY 2019. We estimate that all of the payment and policy changes affecting operating MS-DRG payments, including those affecting Medicare DSH amounts and the hospice transfer payment policy, will result in an estimated 2.0% increase in our annual Medicare FFS IPPS payments, which yields an estimated increase of approximately $40 million. Because of the uncertainty associated with various factors that may influence our future IPPS payments by individual hospital, including legislative or legal actions, admission volumes, length of stay and case mix, we cannot provide any assurances regarding our estimate of the impact of the payment and policy changes.
Payment and Policy Changes to the Medicare Outpatient Prospective Payment and Ambulatory Surgery Center Payment Systems
On November 2, 2018, CMS released Changes to the Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center (“ASC”) Payment System for calendar year (“CY”) 2019 (“Final OPPS/ASC Rule”). The Final OPPS/ASC Rule includes the following payment and policy changes:
- An estimated net increase of 1.35% for the OPPS rates based on an estimated market basket increase of 2.9% reduced by market basket index and multifactor productivity reductions required by the ACA of 0.75% and 0.8%, respectively;
- A transition over a two year period to the Medicare physician fee schedule rates for the payment of clinic/office visits provided at off-campus, hospital-based departments that are currently paid under the OPPS (this payment reduction will not be made in a budget-neutral manner and will result in a reduction of approximately 0.6% to total CY 2019 OPPS payments);
- A 2.1% increase to the ASC payment rates; and
- A revision to the definition of “surgery” in the ASC payment system to account for certain “surgery-like” procedures, and the addition of 12 cardiac catheterization procedures and five related procedures to the ASC covered procedures list.
CMS projects that the combined impact of the payment and policy changes in the Final OPPS/ASC Rule will yield an average 0.6% increase in Medicare FFS OPPS payments for all hospitals, an average 0.7% increase in Medicare FFS OPPS payments for hospitals in large urban areas (populations over one million), and an average 1.0% increase in Medicare FFS OPPS payments for proprietary hospitals. Based on CMS’ estimates, the projected annual impact of the payment and policy changes in the Final OPPS/ASC Rule on our hospitals is an increase to Medicare FFS hospital outpatient revenues of approximately $7 million, which represents an increase of approximately 1.1%. Because of the uncertainty associated with various factors that may influence our future OPPS payments, including legislative or legal actions, volumes and case mix, we cannot provide any assurances regarding our estimate of the impact of the payment and policy changes.
PRIVATE INSURANCE
Managed Care
We currently have thousands of managed care contracts with various HMOs and PPOs. HMOs generally maintain a full-service healthcare delivery network comprised of physician, hospital, pharmacy and ancillary service providers that HMO members must access through an assigned “primary care” physician. The member’s care is then managed by his or her primary care physician and other network providers in accordance with the HMO’s quality assurance and utilization review guidelines so that appropriate healthcare can be efficiently delivered in the most cost-effective manner. HMOs typically provide reduced benefits or reimbursement (or none at all) to their members who use non-contracted healthcare providers for non-emergency care.
PPOs generally offer limited benefits to members who use non-contracted healthcare providers. PPO members who use contracted healthcare providers receive a preferred benefit, typically in the form of lower co-pays, co-insurance or deductibles. As employers and employees have demanded more choice, managed care plans have developed hybrid products that combine elements of both HMO and PPO plans, including high-deductible healthcare plans that may have limited benefits, but cost the employee less in premiums.
The amount of our managed care net patient revenues, including Medicare and Medicaid managed care programs, from our Hospital Operations and other segment during the nine months ended September 30, 2018 and 2017 was $6.869 billion and $7.211 billion, respectively. Approximately 64% of our managed care net patient revenues for the nine months ended September 30, 2018 was derived from our top ten managed care payers. National payers generated approximately 43% of our total net managed care revenues. The remainder comes from regional or local payers. At September 30, 2018 and December 31, 2017, approximately 61% and 62%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from managed care payers.
Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. We believe it is reasonably likely for there to be an approximately 3% increase or decrease in the estimated contractual allowances related to managed care plans. Based on reserves at September 30, 2018, a 3% increase or decrease in the estimated contractual allowance would impact the estimated reserves by approximately $13 million. Some of the factors that can contribute to changes in the contractual allowance estimates include: (1) changes in reimbursement levels for procedures, supplies and drugs when threshold levels are triggered; (2) changes in reimbursement levels when stop-loss or outlier limits are reached; (3) changes in the admission status of a patient due to physician orders subsequent to initial diagnosis or testing; (4) final coding of in-house and discharged-not-final-billed patients that change reimbursement levels; (5) secondary benefits determined after primary insurance payments; and (6) reclassification of patients among insurance plans with different coverage and payment levels. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms, as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our operating income. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans.
We expect managed care governmental admissions to continue to increase as a percentage of total managed care admissions over the near term. However, the managed Medicare and Medicaid insurance plans typically generate lower yields than commercial managed care plans, which have been experiencing an improved pricing trend. Although we have benefited from solid year-over-year aggregate managed care pricing improvements for several years, we have seen these improvements moderate in recent years, and we believe the moderation could continue in future years. In the nine months ended September 30, 2018, our commercial managed care net inpatient revenue per admission from the hospitals and related outpatient facilities in our Hospital Operations and other segment was approximately 93% higher than our aggregate yield on a per admission basis from government payers, including managed Medicare and Medicaid insurance plans.
Indemnity
An indemnity-based agreement generally requires the insurer to reimburse an insured patient for healthcare expenses after those expenses have been incurred by the patient, subject to policy conditions and exclusions. Unlike an HMO member, a patient with indemnity insurance is free to control his or her utilization of healthcare and selection of healthcare providers.
SELF-PAY PATIENTS
Self-pay patients are patients who do not qualify for government programs, such as Medicare and Medicaid, do not have some form of private insurance and, therefore, are responsible for their own medical bills. A significant number of our self-pay patients are admitted through our hospitals’ emergency departments and often require high-acuity treatment that is more costly to provide and, therefore, results in higher billings, which are the least collectible of all accounts.
Self-pay accounts pose significant collectability problems. At September 30, 2018 and December 31, 2017, approximately 7% and 6%, respectively, of our net accounts receivable for our Hospital Operations and other segment were due from self-pay patients. Further, a significant portion of our implicit price concessions relates to self-pay patients, as well as co-pays, co-insurance amounts and deductibles owed to us by patients with insurance. We provide revenue cycle management services through Conifer, which is subject to various statutes and regulations regarding consumer protection in areas including finance, debt collection and credit reporting activities. For additional information, see Item 1, Business — Regulations Affecting Conifer’s Operations, in Part I of our Annual Report.
Conifer has performed systematic analyses to focus our attention on the drivers of bad debt expense for each hospital. While emergency department use is the primary contributor to our implicit price concessions in the aggregate, this is not the case at all hospitals. As a result, we have increased our focus on targeted initiatives that concentrate on non-emergency department patients as well. These initiatives are intended to promote process efficiencies in collecting self‑pay accounts, as well as co-pay, co-insurance and deductible amounts owed to us by patients with insurance, that we deem highly collectible. We leverage a statistical-based collections model that aligns our operational capacity to maximize our collections performance. We are dedicated to modifying and refining our processes as needed, enhancing our technology and improving staff training throughout the revenue cycle process in an effort to increase collections and reduce accounts receivable.
Over the longer term, several other initiatives we have previously announced should also help address this challenge. For example, our Compact with Uninsured Patients (“Compact”) is designed to offer managed care-style discounts to certain uninsured patients, which enables us to offer lower rates to those patients who historically had been charged standard gross charges. A significant portion of those charges had previously been written down in our provision for doubtful accounts. Under the Compact, the discount offered to uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through implicit price concessions based on historical collection trends for self-pay accounts and other factors that affect the estimation process.
We also provide charity care to patients who are unable to pay for the healthcare services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid DSH payments. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels. Generally, our method of measuring the estimated costs uses adjusted self-pay/charity patient days multiplied by selected operating expenses (which include salaries, wages and benefits, supplies and other operating expenses) per adjusted patient day. The adjusted self-pay/charity patient days represents actual self-pay/charity patient days adjusted to include self-pay/charity outpatient services by multiplying actual self-pay/charity patient days by the sum of gross self-pay/charity inpatient revenues and gross self-pay/charity outpatient revenues and dividing the results by gross self-pay/charity inpatient revenues. The following table shows our estimated costs (based on selected operating expenses, which exclude the costs of our health plan businesses) of caring for self-pay patients and charity care patients, as well as revenues attributable to Medicaid DSH and other supplemental revenues we recognized, in the three and nine months ended September 30, 2018 and 2017:
| Estimated costs for: | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
|---|---|---|---|---|
| Self-pay patients | $172 | $164 | $477 | $484 |
| Charity care patients | 28 | 29 | 91 | 92 |
| Total | $200 | $193 | $568 | $576 |
| Medicaid DSH and other supplemental revenues | $233 | $140 | $651 | $462 |
The expansion of health insurance coverage in prior periods has resulted in an increase in the number of patients using our facilities who have either health insurance exchange or government healthcare insurance program coverage. However, we continue to have to provide uninsured discounts and charity care due to the failure of states to expand Medicaid coverage and for persons living in the country illegally who are not permitted to enroll in a health insurance exchange or government healthcare insurance program. Furthermore, in October 2017, the Trump administration announced that reimbursements to insurance companies for ACA cost-sharing reduction (“CSR”) plans offered through the health insurance marketplace would be discontinued. CSR payments compensate insurers for subsidizing out-of-pocket costs for low-income enrollees. Without the CSR payments, some insurers may seek approval to increase premiums for plans offered on ACA exchanges or withdraw from offering plans on some or all of the exchanges. We cannot predict what actions insurers might take as a result of the order, the impact of those actions on our operations, or the outcome of legislative efforts or litigation seeking to restore the payments. We also do not know what adverse impact the continued uncertainty may have on marketplace enrollment and coverage.
RESULTS OF OPERATIONS
The following two tables summarize our consolidated net operating revenues, operating expenses and operating income from continuing operations, both in dollar amounts and as percentages of net operating revenues, for the three and nine months ended September 30, 2018 and 2017:
| Net operating revenues: | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
|---|---|---|---|---|
| Hospital Operations and other | $3,762 | $4,212 | $11,442 | $13,148 |
| Ambulatory Care | 502 | 477 | 1,531 | 1,422 |
| Conifer | 371 | 401 | 1,161 | 1,203 |
| Inter-segment eliminations | (146) | (149) | (440) | (463) |
| Net operating revenues before provision for doubtful accounts | 4,489 | 4,941 | 13,694 | 15,310 |
| Less provision for doubtful accounts | — | 355 | — | 1,109 |
| Net operating revenues | 4,489 | 4,586 | 13,694 | 14,201 |
| Equity in earnings of unconsolidated affiliates | 33 | 38 | 97 | 95 |
| Operating expenses: | ||||
| Salaries, wages and benefits | 2,116 | 2,264 | 6,478 | 6,990 |
| Supplies | 726 | 740 | 2,248 | 2,285 |
| Other operating expenses, net | 1,094 | 1,120 | 3,181 | 3,466 |
| Electronic health record incentives | — | (1) | (1) | (8) |
| Depreciation and amortization | 204 | 219 | 602 | 662 |
| Impairment and restructuring charges, and acquisition-related costs | 46 | 329 | 123 | 403 |
| Litigation and investigation costs | 9 | 6 | 28 | 12 |
| Net losses (gains) on sales, consolidation and deconsolidation of facilities | 7 | (104) | (111) | (142) |
| Operating income | $320 | $51 | $1,243 | $628 |
| Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 | |
|---|---|---|---|---|
| Net operating revenues | 100.0% | 100.0% | 100.0% | 100.0% |
| Equity in earnings of unconsolidated affiliates | 0.7% | 0.8% | 0.7% | 0.7% |
| Operating expenses: | ||||
| Salaries, wages and benefits | 47.1% | 49.4% | 47.3% | 49.3% |
| Supplies | 16.2% | 16.1% | 16.4% | 16.1% |
| Other operating expenses, net | 24.4% | 24.4% | 23.2% | 24.4% |
| Electronic health record incentives | —% | —% | —% | (0.1)% |
| Depreciation and amortization | 4.5% | 4.8% | 4.4% | 4.7% |
| Impairment and restructuring charges, and acquisition-related costs | 1.0% | 7.2% | 0.9% | 2.8% |
| Litigation and investigation costs | 0.2% | 0.1% | 0.2% | 0.1% |
| Net losses (gains) on sales, consolidation and deconsolidation of facilities | 0.2% | (2.3)% | (0.8)% | (1.0)% |
| Operating income | 7.1% | 1.1% | 9.1% | 4.4% |
Total net operating revenues decreased by $97 million and $507 million, or 2.1% and 3.6%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively. Hospital Operations and other and Ambulatory Care net operating revenues and provision for doubtful accounts were impacted by our adoption of ASU 2014-09 effective January 1, 2018. Prior to the adoption of ASU 2014-09, a significant portion of our provision for doubtful accounts related to self-pay patients, as well as co-pays, co-insurance amounts and deductibles owed to us by patients with insurance. Under ASU 2014-09, the estimated uncollectable amounts due from these patients are generally considered implicit price concessions that are a direct reduction to net operating revenues, with a corresponding material reduction in the amounts presented separately as provision for doubtful accounts. Hospital Operations and other net operating revenues net of implicit price concessions and provision for doubtful accounts decreased by $104 million and $624 million, or 2.7% and 5.2%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively, primarily due to the divestiture or closure of eight hospitals since the 2017 period, as well as decreased revenues from our health plans, most of which were sold or winding down in 2017. The three and nine months ended September 30, 2018 included $71 million and $198 million, respectively, of net revenues from the California provider fee program compared to no revenue recorded under this program in the 2017 periods because the extension of the program had not yet been approved by CMS. Ambulatory Care net operating revenues net of implicit price concessions and provision for doubtful accounts increased $34 million and $136 million, or 7.3% and 9.7%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively. The growth in 2018 revenues was driven by increases in same-facility net operating revenues of $35 million and $96 million, partially offset by decreases due to the sale of Aspen of $21 million and $12 million, in each case for the three and nine month periods, respectively. Acquisitions increased 2018 revenues by $20 million and $52 million for the three and nine month periods, respectively. Conifer net operating revenues decreased $30 million and $42 million, or 7.5% and 3.5%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively.
The following table shows selected operating expenses of our three reportable business segments. Information for our Hospital Operations and other segment is presented on a same-hospital basis, which includes the results of our same 68 hospitals operated throughout the nine months ended September 30, 2018 and 2017. The results of three Houston-area hospitals, which we divested effective August 1, 2017, Abrazo Maryvale Campus, which we closed in December 2017, two Philadelphia-area hospitals, which we divested effective January 11, 2018, MacNeal Hospital, which we divested effective March 1, 2018, and Des Peres Hospital, which we divested effective May 1, 2018, are excluded from our same-hospital information. In addition, although we operated four North Texas hospitals throughout the nine months ended September 30, 2017 and from January 1 through February 28, 2018, we did not consolidate the results of operations of these hospitals because we divested a controlling interest in them effective January 1, 2016.
| Selected Operating Expenses Hospital Operations and other — Same-Hospital | Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Salaries, wages and benefits | $1,746 | $1,716 | 1.7% | $5,294 | $5,212 | 1.6% |
| Supplies | 621 | 592 | 4.9% | 1,907 | 1,815 | 5.1% |
| Other operating expenses | 929 | 800 | 16.1% | 2,625 | 2,491 | 5.4% |
| Total | $3,296 | $3,108 | 6.0% | $9,826 | $9,518 | 3.2% |
| Ambulatory Care | ||||||
| Salaries, wages and benefits | $157 | $155 | 1.3% | $484 | $458 | 5.7% |
| Supplies | 104 | 95 | 9.5% | 316 | 285 | 10.9% |
| Other operating expenses | 88 | 93 | (5.4)% | 275 | 267 | 3.0% |
| Total | $349 | $343 | 1.7% | $1,075 | $1,010 | 6.4% |
| Conifer | ||||||
| Salaries, wages and benefits | $213 | $230 | (7.4)% | $652 | $730 | (10.7)% |
| Supplies | 1 | 1 | —% | 4 | 3 | 33.3% |
| Other operating expenses | 76 | 91 | (16.5)% | 235 | 266 | (11.7)% |
| Total | $290 | $322 | (9.9)% | $891 | $999 | (10.8)% |
| Total | ||||||
| Salaries, wages and benefits | $2,116 | $2,101 | 0.7% | $6,430 | $6,400 | 0.5% |
| Supplies | 726 | 688 | 5.5% | 2,227 | 2,103 | 5.9% |
| Other operating expenses | 1,093 | 984 | 11.1% | 3,135 | 3,024 | 3.7% |
| Total | $3,935 | $3,773 | 4.3% | $11,792 | $11,527 | 2.3% |
| Rent/lease expense(1) | ||||||
| Hospital Operations and other | $57 | $56 | 1.8% | $171 | $166 | 3.0% |
| Ambulatory Care | 20 | 20 | —% | 60 | 57 | 5.3% |
| Conifer | 4 | 4 | —% | 13 | 14 | (7.1)% |
| Total | $81 | $80 | 1.3% | $244 | $237 | 3.0% |
(1) Included in other operating expenses.
RESULTS OF OPERATIONS BY SEGMENT
Our operations are reported in three segments:
- Hospital Operations and other, which is comprised of our acute care and specialty hospitals, ancillary outpatient facilities, urgent care centers, microhospitals and physician practices. As described in Note 4 to the accompanying Condensed Consolidated Financial Statements, certain of our facilities are classified as held for sale at September 30, 2018.
- Ambulatory Care, which is comprised of USPI’s ambulatory surgery centers, urgent care centers, imaging centers and surgical hospitals (and also included nine facilities in the United Kingdom until we divested Aspen effective August 17, 2018).
- Conifer, which provides healthcare business process services in the areas of hospital and physician revenue cycle management and value-based care solutions to healthcare systems, as well as individual hospitals, physician practices, self-insured organizations, health plans and other entities.
Hospital Operations and Other Segment
The following tables show operating statistics of our continuing operations hospitals and related outpatient facilities on a same-hospital basis, unless otherwise indicated, which includes the results of our same 68 hospitals operated throughout the nine months ended September 30, 2018 and 2017. The results of three Houston-area hospitals, which we divested effective August 1, 2017, Abrazo Maryvale Campus, which we closed in December 2017, two Philadelphia-area hospitals, which we divested effective January 11, 2018, MacNeal Hospital, which we divested effective March 1, 2018, and Des Peres Hospital, which we divested effective May 1, 2018, are excluded from our same-hospital information. In addition, although we operated four North Texas hospitals throughout the nine months ended September 30, 2017 and from January 1 through February 28, 2018, we did not consolidate the results of operations of these hospitals because we divested a controlling interest in them effective January 1, 2016.
| Admissions, Patient Days and Surgeries | Same-Hospital Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | Same-Hospital Continuing Operations Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease) | ||
|---|---|---|---|---|---|---|---|---|
| Number of hospitals (at end of period) | 68 | 68 | — | (1) | 68 | 68 | — | (1) |
| Total admissions | 168,202 | 171,766 | (2.1)% | 514,526 | 521,438 | (1.3)% | ||
| Adjusted patient admissions(2) | 306,199 | 305,300 | 0.3% | 924,037 | 921,715 | 0.3% | ||
| Paying admissions (excludes charity and uninsured) | 157,197 | 161,743 | (2.8)% | 483,655 | 492,896 | (1.9)% | ||
| Charity and uninsured admissions | 11,005 | 10,023 | 9.8% | 30,871 | 28,542 | 8.2% | ||
| Admissions through emergency department | 116,727 | 112,210 | 4.0% | 354,594 | 337,463 | 5.1% | ||
| Paying admissions as a percentage of total admissions | 93.5% | 94.2% | (0.7)% | (1) | 94.0% | 94.5% | (0.5)% | (1) |
| Charity and uninsured admissions as a percentage of total admissions | 6.5% | 5.8% | 0.7% | (1) | 6.0% | 5.5% | 0.5% | (1) |
| Emergency department admissions as a percentage of total admissions | 69.4% | 65.3% | 4.1% | (1) | 68.9% | 64.7% | 4.2% | (1) |
| Surgeries — inpatient | 45,626 | 47,315 | (3.6)% | 137,623 | 141,503 | (2.7)% | ||
| Surgeries — outpatient | 61,468 | 61,562 | (0.2)% | 186,132 | 187,316 | (0.6)% | ||
| Total surgeries | 107,094 | 108,877 | (1.6)% | 323,755 | 328,819 | (1.5)% | ||
| Patient days — total | 761,921 | 789,040 | (3.4)% | 2,368,366 | 2,414,961 | (1.9)% | ||
| Adjusted patient days(2) | 1,365,664 | 1,379,096 | (1.0)% | 4,186,068 | 4,203,108 | (0.4)% | ||
| Average length of stay (days) | 4.53 | 4.59 | (1.3)% | 4.60 | 4.63 | (0.6)% | ||
| Licensed beds (at end of period) | 17,934 | 18,006 | (0.4)% | 17,934 | 18,006 | (0.4)% | ||
| Average licensed beds | 17,934 | 18,007 | (0.4)% | 17,942 | 17,983 | (0.2)% | ||
| Utilization of licensed beds(3) | 46.2% | 47.6% | (1.4)% | (1) | 48.4% | 49.2% | (0.8)% | (1) |
(1) The change is the difference between 2018 and 2017 amounts shown.
(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
(3) Utilization of licensed beds represents patient days divided by number of days in the period divided by average licensed beds.
46
| Outpatient Visits | Same-Hospital Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | Same-Hospital Continuing Operations Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease) | ||
|---|---|---|---|---|---|---|---|---|
| Total visits | 1,722,292 | 1,715,650 | 0.4% | 5,264,505 | 5,293,076 | (0.5)% | ||
| Paying visits (excludes charity and uninsured) | 1,607,180 | 1,600,195 | 0.4% | 4,919,392 | 4,951,644 | (0.7)% | ||
| Charity and uninsured visits | 115,112 | 115,455 | (0.3)% | 345,113 | 341,432 | 1.1% | ||
| Emergency department visits | 638,248 | 627,415 | 1.7% | 1,963,474 | 1,923,995 | 2.1% | ||
| Surgery visits | 61,468 | 61,562 | (0.2)% | 186,132 | 187,316 | (0.6)% | ||
| Paying visits as a percentage of total visits | 93.3% | 93.3% | —% | (1) | 93.4% | 93.5% | (0.1)% | (1) |
| Charity and uninsured visits as a percentage of total visits | 6.7% | 6.7% | —% | (1) | 6.6% | 6.5% | 0.1% | (1) |
(1) The change is the difference between 2018 and 2017 amounts shown.
| Revenues | Same-Hospital Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | Same-Hospital Continuing Operations Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Total segment net operating revenues(1) | $3,613 | $3,367 | 7.3% | $10,899 | $10,350 | 5.3% |
| Selected revenue data – hospitals and related outpatient facilities | ||||||
| Net patient revenues(1)(2) | $3,432 | $3,237 | 6.0% | $10,434 | $9,905 | 5.3% |
| Net patient revenue per adjusted patient admission(1)(2) | $11,208 | $10,603 | 5.7% | $11,292 | $10,746 | 5.1% |
| Net patient revenue per adjusted patient day(1)(2) | $2,513 | $2,347 | 7.1% | $2,493 | $2,357 | 5.8% |
(1) Revenues are net of implicit price concessions and provision for doubtful accounts.
(2) Adjusted patient admissions/days represents actual patient admissions/days adjusted to include outpatient services provided by facilities in our Hospital Operations and other segment by multiplying actual patient admissions/days by the sum of gross inpatient revenues and outpatient revenues and dividing the results by gross inpatient revenues.
| Total Segment Selected Operating Expenses | Same-Hospital Continuing Operations Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | Same-Hospital Continuing Operations Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease) | ||
|---|---|---|---|---|---|---|---|---|
| Salaries, wages and benefits as a percentage of net operating revenues | 48.3% | 51.0% | (2.7)% | (1) | 48.6% | 50.4% | (1.8)% | (1) |
| Supplies as a percentage of net operating revenues | 17.2% | 17.6% | (0.4)% | (1) | 17.5% | 17.5% | —% | (1) |
| Other operating expenses as a percentage of net operating revenues | 25.7% | 23.8% | 1.9% | (1) | 24.1% | 24.1% | —% | (1) |
(1) The change is the difference between 2018 and 2017 amounts shown.
Revenues
Same-hospital net operating revenues increased $246 million, or 7.3%, during the three months ended September 30, 2018 compared to the three months ended September 30, 2017, primarily due improved terms of our managed care contracts and California provider fee revenues. The 2018 period included $71 million of net revenues from the California provider fee program compared to no revenue recorded under this program in the 2017 period because the extension of the program had not yet been approved by CMS. Same-hospital admissions decreased 2.1% in the three months ended September 30, 2018 compared to the same period in 2017. Same-hospital outpatient visits increased 0.4% in the three months ended September 30, 2018 compared to the same period in 2017.
Same-hospital net operating revenues increased $549 million, or 5.3%, during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017, primarily due improved terms of our managed care contracts and California provider fee revenues. The 2018 period included $198 million of net revenues from the California provider fee program compared to no revenue recorded under this program in the 2017 period because the extension of the program had not yet been approved by CMS. Same-hospital admissions decreased 1.3% in the nine months ended September 30, 2018 compared to the same period in 2017. Same-hospital outpatient visits decreased 0.5% in the nine months ended September 30, 2018 compared to the same period in 2017.
The following table shows the consolidated net accounts receivable by payer at September 30, 2018 and the consolidated net accounts receivable and allowance for doubtful accounts by payer at December 31, 2017:
| September 30, 2018 Accounts Receivable | December 31, 2017 Accounts Receivable Before Allowance for Doubtful Accounts | Allowance for Doubtful Accounts | Net | |
|---|---|---|---|---|
| Medicare | $205 | $257 | $— | $257 |
| Medicaid | 80 | 95 | — | 95 |
| Net cost report settlements receivable and valuation allowances | 7 | 4 | — | 4 |
| Managed care | 1,407 | 1,709 | 204 | 1,505 |
| Self-pay uninsured | 29 | 407 | 351 | 56 |
| Self-pay balance after insurance | 126 | 240 | 149 | 91 |
| Estimated future recoveries | 139 | 132 | — | 132 |
| Other payers | 329 | 453 | 151 | 302 |
| Total Hospital Operations and other | 2,322 | 3,297 | 855 | 2,442 |
| Ambulatory Care | 160 | 215 | 43 | 172 |
| Total discontinued operations | 2 | 2 | — | 2 |
| $2,484 | $3,514 | $898 | $2,616 |
For patient accounts receivable resulting from revenue recognized prior to January 1, 2018, an allowance for doubtful accounts was established to reduce the carrying value of such receivables to their estimated net realizable value. Generally, we estimated this allowance based on the aging of our accounts receivable by hospital, our historical collection experience by hospital and for each type of payer, and other relevant factors. Under the provisions of ASU 2014-09, which we adopted effective January 1, 2018, when we have an unconditional right to payment, subject only to the passage of time, the right is treated as a receivable. Patient accounts receivable, including billed accounts and unbilled accounts for which we have the unconditional right to payment, and estimated amounts due from third-party payers for retroactive adjustments, are receivables if our right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. For patient accounts receivable subsequent to our adoption of ASU 2014-09 on January 1, 2018, the estimated uncollectable amounts are generally considered implicit price concessions that are a direct reduction to patient accounts receivable rather than allowance for doubtful accounts. Under the provisions of ASU 2014-09, amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations and other segment, our contract assets consist primarily of services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations and other segment’s contract assets are included in other current assets on the accompanying Condensed Consolidated Balance Sheet at September 30, 2018. Prior to January 1, 2018, amounts related to services provided to patients for which we had not billed were included in accounts receivable, less allowance for doubtful accounts, on our consolidated balance sheets.
Collection of accounts receivable has been a key area of focus, particularly over the past several years. At September 30, 2018, our Hospital Operations and other segment collection rate on self-pay accounts was approximately 23.4%. Our self-pay collection rate includes payments made by patients, including co-pays, co-insurance amounts and deductibles paid by patients with insurance. Based on our accounts receivable from self-pay patients and co-pays, co-insurance amounts and deductibles owed to us by patients with insurance at September 30, 2018, a 10% decrease or increase in our self-pay collection rate, or approximately 3%, which we believe could be a reasonably likely change, would result in an unfavorable or favorable adjustment to patient accounts receivable of approximately $11 million.
Payment pressure from managed care payers also affects the collectability of our accounts receivable. We typically experience ongoing managed care payment delays and disputes; however, we continue to work with these payers to obtain adequate and timely reimbursement for our services. Our estimated Hospital Operations and other segment collection rate from managed care payers was approximately 98.5% at September 30, 2018.
We manage our implicit price concessions using hospital-specific goals and benchmarks such as (1) total cash collections, (2) point-of-service cash collections, (3) AR Days and (4) accounts receivable by aging category. The following tables present the approximate aging by payer of our net accounts receivable from the continuing operations of our Hospital Operations and other segment of $2.315 billion and $2.438 billion at September 30, 2018 and December 31, 2017, respectively, excluding cost report settlements receivable and valuation allowances of $7 million and $4 million, respectively, at September 30, 2018 and December 31, 2017:
| September 30, 2018 Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total | |
|---|---|---|---|---|---|
| 0-60 days(1) | 88% | 53% | 58% | 29% | 54% |
| 61-120 days | 6% | 21% | 15% | 17% | 15% |
| 121-180 days | 2% | 11% | 9% | 10% | 8% |
| Over 180 days | 4% | 15% | 18% | 44% | 23% |
| Total | 100% | 100% | 100% | 100% | 100% |
(1) The 0-60 days aging category has been impacted by the reclassification of certain unbilled accounts to contract assets due to the adoption of ASU 2014-09 effective January 1, 2018. See Notes 1 and 3 to our accompanying Condensed Consolidated Financial Statements for additional information.
| December 31, 2017 Medicare | Medicaid | Managed Care | Indemnity, Self-Pay and Other | Total | |
|---|---|---|---|---|---|
| 0-60 days | 89% | 66% | 65% | 28% | 60% |
| 61-120 days | 6% | 16% | 14% | 17% | 13% |
| 121-180 days | 2% | 10% | 7% | 9% | 7% |
| Over 180 days | 3% | 8% | 14% | 46% | 20% |
| Total | 100% | 100% | 100% | 100% | 100% |
Conifer continues to implement revenue cycle initiatives to improve our cash flow. These initiatives are focused on standardizing and improving patient access processes, including pre-registration, registration, verification of eligibility and benefits, liability identification and collections at point-of-service, and financial counseling. These initiatives are intended to reduce denials, improve service levels to patients and increase the quality of accounts that end up in accounts receivable. Although we continue to focus on improving our methodology for evaluating the collectability of our accounts receivable, we may incur future charges if there are unfavorable changes in the trends affecting the net realizable value of our accounts receivable.
At September 30, 2018, we had a cumulative total of patient account assignments to Conifer of approximately $2.517 billion related to our continuing operations. These accounts have already been written off and are not included in our receivables or in the allowance for doubtful accounts; however, an estimate of future recoveries from all the accounts assigned to Conifer is determined based on our historical experience and recorded in accounts receivable.
Patient advocates from Conifer’s Medicaid Eligibility Program (“MEP”) screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs. Receivables from patients who are potentially eligible for Medicaid are classified as
Medicaid pending, under the MEP, with appropriate contractual allowances recorded. Based on recent trends, approximately 96% of all accounts in the MEP are ultimately approved for benefits under a government program, such as Medicaid. The following table shows the approximate amount of accounts receivable in the MEP still awaiting determination of eligibility under a government program at September 30, 2018 and December 31, 2017 by aging category for the hospitals currently in the program:
| September 30, 2018 | December 31, 2017 | |
|---|---|---|
| 0-60 days | $71 | $81 |
| 61-120 days | 10 | 12 |
| 121-180 days | 3 | 3 |
| Over 180 days | 3 | 4 |
| Total | $87 | $100 |
Salaries, Wages and Benefits
Same-hospital salaries, wages and benefits as a percentage of net operating revenues decreased 270 basis points to 48.3% in the three months ended September 30, 2018 compared to the same period in 2017. Same-hospital net operating revenues increased 7.3% during the three months ended September 30, 2018 compared to the three months ended September 30, 2017, and same-hospital salaries, wages and benefits increased 1.7% in the three months ended September 30, 2018 compared to the 2017 period. The change in same-hospital salaries, wages and benefits as a percentage of net operating revenues was primarily due to the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives and the impact of favorable workers’ compensation claims experience, partially offset by annual merit increases for certain of our employees and increased health benefits costs. Salaries, wages and benefits expense for the three months ended September 30, 2018 and 2017 included stock-based compensation expense of $7 million and $10 million, respectively.
Same-hospital salaries, wages and benefits as a percentage of net operating revenues decreased 180 basis points to 48.6% in the nine months ended September 30, 2018 compared to the same period in 2017. Same-hospital net operating revenues increased 5.3% during the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017, and same-hospital salaries, wages and benefits increased 1.6% in the nine months ended September 30, 2018 compared to the 2017 period. The change in same-hospital salaries, wages and benefits as a percentage of net operating revenues was primarily due to the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives and the impact of favorable workers’ compensation claims experience, partially offset by annual merit increases for certain of our employees and increased health benefits costs. Salaries, wages and benefits expense for the nine months ended September 30, 2018 and 2017 included stock-based compensation expense of $20 million and $32 million, respectively.
At September 30, 2018, approximately 25% of the employees in our Hospital Operations and other segment were represented by labor unions. Less than 1% of employees in our Ambulatory Care and Conifer segments belong to a union. Unionized employees – primarily registered nurses and service, technical and maintenance workers – are located at 33 of our hospitals, the majority of which are in California, Florida and Michigan. We currently have eight expired contracts covering approximately 14% of our unionized employees and are or will be negotiating renewals under extension agreements. We are also negotiating (or will soon negotiate) five first contracts at five hospitals where employees recently selected union representation; these contracts will cover nearly 5% of our unionized employees. At this time, we are unable to predict the outcome of the negotiations, but increases in salaries, wages and benefits could result from these agreements. Furthermore, there is a possibility that strikes could occur during the negotiation process, which could increase our labor costs and have an adverse effect on our patient admissions and net operating revenues. Organizing activities by labor unions could increase our level of union representation in future periods.
Supplies
Same-hospital supplies expense as a percentage of net operating revenues decreased 40 basis points to 17.2% in the three months ended September 30, 2018 compared to the same period in 2017. Same-hospital supplies expense as a percentage of net operating revenues was 17.5% for both of the nine month periods ended September 30, 2018 and 2017. Supplies expense was impacted by increased costs from certain higher acuity supply-intensive surgical services.
We strive to control supplies expense through product standardization, contract compliance, improved utilization, bulk purchases and operational improvements. The items of current cost reduction focus continue to be cardiac stents and pacemakers, orthopedics and implants, and high-cost pharmaceuticals.
Other Operating Expenses, Net
Same-hospital other operating expenses as a percentage of net operating revenues increased 190 basis points to 25.7% in the three months ended September 30, 2018 compared to 23.8% in the same period in 2017. Same-hospital other operating expenses increased by $129 million, or 16.1%, and net operating revenues increased by $246 million, or 7.3%, for the three months ended September 30, 2018 compared to the three months ended September 30, 2017. The changes in other operating expenses included:
- increased malpractice expense of $53 million to settle various claims;
- increased medical fees of $49 million, due in part to unfavorable claims experience on risk-based capitated contracts in California; and
- increased technology and software costs of $19 million; partially offset by
- gains on the sales of assets of $19 million in the 2018 period primarily related to the sale of an equity method investment.
Same-hospital malpractice expense in the 2018 period included a favorable adjustment of approximately $5 million from a 20 basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2017 period, we recognized a favorable adjustment of approximately $1 million from a two basis point increase in the discounted present value of projected future malpractice liabilities.
Same-hospital other operating expenses as a percentage of net operating revenues was 24.1% for both of the nine month periods ended September 30, 2018 and 2017. Same-hospital other operating expenses increased by $134 million, or 5.4%, and net operating revenues increased by $549 million, or 5.3%, for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017. The changes in other operating expenses included:
- increased malpractice expense of $64 million to settle various claims;
- increased medical fees of $75 million, due in part to unfavorable claims experience on risk-based capitated contracts in California; and
- increased technology and software costs of $36 million; partially offset by
- decreased expenses associated with our health plan businesses of $99 million due to the sale and wind-down of these businesses in 2017.
Same-hospital malpractice expense in the 2018 period included a favorable adjustment of approximately $18 million from a 68 basis point increase in the interest rate used to estimate the discounted present value of projected future malpractice liabilities. In the 2017 period, we recognized an unfavorable adjustment of approximately $1 million from a nine basis point decrease in the discounted present value of projected future malpractice liabilities.
Ambulatory Care Segment
Our Ambulatory Care segment is comprised of USPI’s ambulatory surgery centers, urgent care centers, imaging centers and surgical hospitals. Our Ambulatory Care segment also included nine facilities in the United Kingdom until we divested Aspen effective August 17, 2018. USPI operates its surgical facilities in partnership with local physicians and, in many of these facilities, a healthcare system partner. We hold an ownership interest in each facility, with each being operated through a separate legal entity in most cases. USPI operates facilities on a day-to-day basis through management services contracts. Our sources of earnings from each facility consist of:
- management services revenues, computed as a percentage of each facility’s net revenues (often net of implicit price concessions); and
- our share of each facility’s net income (loss), which is computed by multiplying the facility’s net income (loss) times the percentage of each facility’s equity interests owned by USPI.
Our role as an owner and day-to-day manager provides us with significant influence over the operations of each facility. In many of the facilities our Ambulatory Care segment operates (107 of 335 facilities at September 30, 2018), this influence does not represent control of the facility, so we account for our investment in the facility under the equity method for an unconsolidated affiliate. USPI controls 228 of the facilities our Ambulatory Care segment operates, and we account for these investments as consolidated subsidiaries. Our net earnings from a facility are the same under either method, but the classification of those earnings differs. For consolidated subsidiaries, our financial statements reflect 100% of the revenues and expenses of the subsidiaries, after the elimination of intercompany amounts. The net profit attributable to owners other than USPI is classified within “net income available to noncontrolling interests.”
For unconsolidated affiliates, our consolidated statements of operations reflect our earnings in two line items:
- *equity in earnings of unconsolidated affiliates—*our share of the net income (loss) of each facility, which is based on the facility’s net income (loss) and the percentage of the facility’s outstanding equity interests owned by us; and
- *management and administrative services revenues, which is included in our net operating revenues—*income we earn for managing the day-to-day operations of each facility, usually quantified as a percentage of each facility’s net revenues less implicit price concessions.
Our Ambulatory Care segment operating income is driven by the performance of all facilities USPI operates and by USPI’s ownership interests in those facilities, but our individual revenue and expense line items contain only consolidated businesses, which represent 68% of those facilities. This translates to trends in consolidated operating income that often do not correspond with changes in consolidated revenues and expenses.
Results of Operations
The following table summarizes certain consolidated statements of operations items for the periods indicated:
| Ambulatory Care Results of Operations | Three Months Ended September 30, 2018 | 2017 | Increase (Decrease) | Nine Months Ended September 30, 2018 | 2017 | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Net operating revenues | $502 | $468 | 7.3% | $1,531 | $1,395 | 9.7% |
| Equity in earnings of unconsolidated affiliates | $31 | $34 | (8.8)% | $91 | $91 | —% |
| Salaries, wages and benefits | $157 | $155 | 1.3% | $484 | $458 | 5.7% |
| Supplies | $104 | $95 | 9.5% | $316 | $285 | 10.9% |
| Other operating expenses, net | $88 | $93 | (5.4)% | $275 | $267 | 3.0% |
Our Ambulatory Care net operating revenues increased $34 million and $136 million, or 7.3% and 9.7%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively. The growth in 2018 revenues was driven by increases in same-facility net operating revenues of $35 million and $96 million, partially offset by decreases due to the sale of Aspen of $21 million and $12 million, in each case for the three and nine month periods, respectively. Acquisitions increased 2018 revenues by $20 million and $52 million for the three and nine month periods, respectively.
Salaries, wages and benefits expense increased by $2 million and $26 million, or 1.3% and 5.7%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively. The change during the three months ended September 30, 2018 was driven by an increase in same-facility salaries, wages and benefits expense of $5 million, an increase from acquisitions of $5 million and a decrease due to the sale of Aspen of $8 million. The change during the nine months ended September 30, 2018 was driven by an increase in same-facility salaries, wages and benefits expense of $15 million, an increase from acquisitions of $15 million and a decrease due to the sale of Aspen of $4 million.
Supplies expense increased by $9 million and $31 million, or 9.5% and 10.9%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively. The change during the three months ended September 30, 2018 was driven by an increase in same-facility supplies expense of $9 million, an increase from acquisitions of $5 million and a decrease due to the sale of Aspen of $5 million. The change during the nine months ended September 30, 2018 was driven by an increase in same-facility supplies expense of $22 million, an increase from acquisitions of $12 million and a decrease due to the sale of Aspen of $3 million.
Other operating expenses decreased by $5 million, or 5.4%, and increased by $8 million, or 3.0%, for the three and nine months ended September 30, 2018, respectively, compared to the three and nine months ended September 30, 2017, respectively. The change for the three months ended September 30, 2018 was driven by a decrease in same-facility other operating expenses of $2 million, an increase from acquisitions of $3 million and a decrease due to the sale of Aspen of $6 million. The change for the nine months ended September 30, 2018 was driven by an increase in same-facility other operating expenses of $1 million, an increase from acquisitions of $10 million and a decrease due to the sale of Aspen of $3 million.
Facility Growth
The following table summarizes the changes in our same-facility revenue year-over-year on a pro forma systemwide basis, which includes both consolidated and unconsolidated (equity method) facilities. While we do not record the revenues of unconsolidated facilities, we believe this information is important in understanding the financial performance of our Ambulatory Care segment because these revenues are the basis for calculating our management services revenues and, together with the expenses of our unconsolidated facilities, are the basis for our equity in earnings of unconsolidated affiliates.
| Ambulatory Care Facility Growth | Three Months Ended September 30, 2018 | Nine Months Ended September 30, 2018 |
|---|---|---|
| Net revenues | 6.7% | 5.6% |
| Cases | 5.0% | 4.3% |
| Net revenue per case | 1.6% | 1.3% |
Joint Ventures with Healthcare System Partners
USPI’s business model is to jointly own its facilities with local physicians and, in many of these facilities, a not-for-profit healthcare system partner. Accordingly, as of September 30, 2018, the majority of facilities in our Ambulatory Care segment are operated in this model.
| Ambulatory Care Facilities Facilities: | Nine Months Ended September 30, 2018 |
|---|---|
| With a healthcare system partner | 205 |
| Without a healthcare system partner | 130 |
| Total facilities operated | 335 |
| Change from December 31, 2017 | |
| Acquisitions | 7 |
| De novo | 7 |
| Dispositions/Mergers | (12) |
| Total increase in number of facilities operated | 2 |
During the nine months ended September 30, 2018, we sold our nine Aspen facilities in the United Kingdom, and we acquired controlling interests in an ophthalmology surgery center in Pennsylvania, a single-specialty spine surgery center in Georgia, multi-specialty surgery centers in Florida and Texas, and a single specialty gastroenterology center in Florida. We paid cash totaling approximately $89 million for these acquisitions. We also acquired a noncontrolling ownership interest in a multi-specialty surgery center in California for approximately $7 million. All six facilities are jointly owned with local physicians.
Also during the nine months ended September 30, 2018, we acquired controlling interests in four facilities in which we already had an equity method investment. These multi-specialty surgery centers are located in New Jersey and Georgia. We paid cash totaling approximately $7 million for the additional ownership interests. All four facilities are jointly owned with local physicians. Furthermore, during the nine months ended September 30, 2018, the Ambulatory Care segment acquired the non-controlling interest in Baylor Scott & White Medical Center – Sunnyvale, a surgical hospital in Texas, previously held by the Hospital Operations and other segment. The facility is jointly owned with local physicians and a healthcare system partner.
Conifer Segment
Our Conifer segment generated net operating revenues of $371 million and $401 million during the three months ended September 30, 2018 and 2017, respectively, and $1.161 billion and $1.203 billion during the nine months ended September 30, 2018 and 2017, respectively, a portion of which was eliminated in consolidation as described in Note 18 to the accompanying Condensed Consolidated Financial Statements. Conifer revenues from third-party customers, which are not eliminated in consolidation, decreased $27 million, or 10.7%, for the three months ended September 30, 2018 compared to the three months ended September 30, 2017. Conifer revenues from third-party customers were negatively impacted by contract terminations related to the sales of customer hospitals, offset by the impact of the divestiture of former Tenet facilities that have now become third-party customers. Conifer revenues from third-party customers decreased $19 million, or 2.6%, for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017, due primarily to contract terminations related to the sale of customer hospitals to healthcare systems that chose to insource revenue cycle management.
Salaries, wages and benefits expense for Conifer decreased $17 million, or 7.4%, in the three months ended September 30, 2018 compared to the three months ended September 30, 2017, and decreased $78 million, or 10.7%, in the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017, in both cases primarily due to the impact of previously announced workforce reductions as part of our enterprise-wide cost reduction initiatives.
Other operating expenses for Conifer decreased $15 million, or 16.5%, in the three months ended September 30, 2018 compared to the three months ended September 30, 2017, and decreased $31 million, or 11.7%, in the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017, in both cases primarily due to the impact of our enterprise-wide cost reduction initiatives.
Consolidated
Impairment and Restructuring Charges, and Acquisition-Related Costs
During the three months ended September 30, 2018, we recorded impairment and restructuring charges and acquisition-related costs of $46 million, consisting of $6 million of impairment charges, $35 million of restructuring charges and $5 million of acquisition-related costs. Impairment charges consisted primarily of $5 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen and $1 million of other impairment charges. Restructuring charges consisted of $21 million of employee severance costs, $5 million of contract and lease termination fees, and $9 million of other restructuring costs. Acquisition-related costs consisted of $3 million of transaction costs and $2 million of acquisition integration charges.
During the three months ended September 30, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $329 million, consisting of $309 million of impairment charges, $17 million of restructuring charges and $3 million of acquisition-related costs. Impairment charges consisted primarily of approximately $294 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, $14 million of impairment of two equity method investments and $1 million to write-down intangible assets. Restructuring charges consisted of $10 million of employee severance costs, $1 million of contract and lease termination fees, and $6 million of other restructuring costs. Acquisition-related costs consisted of $3 million of transaction costs.
During the nine months ended September 30, 2018, we recorded impairment and restructuring charges and acquisition-related costs of $123 million, consisting of $29 million of impairment charges, $82 million of restructuring charges and $12 million of acquisition-related costs. Impairment charges consisted primarily of $17 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for certain of our Chicago-area facilities, $9 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for Aspen and $3 million of other impairment charges. Restructuring charges consisted of $47 million of employee severance costs, $10 million of contract and lease termination fees, and $25 million of other restructuring costs. Acquisition-related costs consisted of $8 million of transaction costs and $4 million of acquisition integration charges.
During the nine months ended September 30, 2017, we recorded impairment and restructuring charges and acquisition-related costs of $403 million, consisting of $326 million of impairment charges, $61 million of restructuring charges and $16 million of acquisition-related costs. Impairment charges consisted primarily of approximately $294 million of charges to write-down assets held for sale to their estimated fair value, less estimated costs to sell, for our Aspen and Philadelphia-area facilities, $29 million of impairment of two equity method investments and $3 million to write-down intangible assets. Restructuring charges consisted of $40 million of employee severance costs, $8 million of contract and lease termination fees, and $13 million of other restructuring costs. Acquisition-related costs consisted of $5 million of transaction costs and $11 million of acquisition integration charges.
Litigation and Investigation Costs
Litigation and investigation costs for the three months ended September 30, 2018 and 2017 were $9 million and $6 million, respectively. Litigation and investigation costs for the nine months ended September 30, 2018 and 2017 were $28 million and $12 million, respectively. The increased costs in the 2018 period relate primarily to attorneys’ fees associated with internal investigations performed pursuant to our non-prosecution agreement (the “NPA”), as well as attorneys’ fees associated with our indemnification obligations with respect to two former employees in connection with criminal charges for conduct described in the NPA.
Net Losses (Gains) on Sales, Consolidation and Deconsolidation of Facilities
During the three months ended September 30, 2018, we recorded net losses on sales, consolidation and deconsolidation of facilities of approximately $7 million, primarily due to a post-closing adjustment to the gain on the sale of MacNeal Hospital.
During the three months ended September 30, 2017, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $104 million, primarily comprised of a $111 million gain from the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area.
During the nine months ended September 30, 2018, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $111 million, primarily comprised of gains of $88 million from the sale of MacNeal Hospital and other operations affiliated with the hospital in the Chicago area, $13 million from the sales of our minority interests in four North Texas hospitals and $12 million from the sale of Des Peres Hospital, physician practices and other hospital-affiliated operations in St. Louis, Missouri.
During the nine months ended September 30, 2017, we recorded net gains on sales, consolidation and deconsolidation of facilities of approximately $142 million, primarily comprised of gains of $111 million from the sale of our hospitals, physician practices and related assets in Houston, Texas and the surrounding area, $13 million from the sale of one of our health plans in Arizona, $10 million from the sale of our health plan in Texas and $3 million from the sale of our health plans in Michigan.
Interest Expense
Interest expense for the three months ended September 30, 2018 was $249 million compared to $257 million for the same period in 2017. Interest expense for the nine months ended September 30, 2018 was $758 million compared to $775 million for the same period in 2017.
Income Tax Expense
During the three months ended September 30, 2018, we recorded income tax expense of $6 million in continuing operations on pre-tax income of $71 million compared to an income tax benefit of $60 million on a pre-tax loss of $348 million during the three months ended September 30, 2017. During the nine months ended September 30, 2018, we recorded income tax expense of $120 million in continuing operations on pre-tax income of $481 million compared to an income tax benefit of $105 million on a pre-tax loss of $325 million during the nine months ended September 30, 2017. The reconciliation between the amount of recorded income tax expense (benefit) and the amount calculated at the statutory federal tax rate is shown in the following table:
| Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 | |
|---|---|---|---|---|
| Tax expense at statutory federal rate of 21% (35% for 2017) | $15 | $(122) | $101 | $(114) |
| State income taxes, net of federal income tax benefit | 3 | 8 | 20 | 13 |
| Tax benefit available to noncontrolling interests | (15) | (25) | (49) | (79) |
| Nondeductible goodwill | — | 104 | 7 | 104 |
| Tax benefit related to loss on Aspen sale | (18) | — | (18) | — |
| Change in tax contingency reserves, including interest | — | (1) | — | (3) |
| Stock-based compensation | — | — | 4 | 9 |
| Change in valuation allowance-interest expense limitation | 24 | — | 54 | — |
| Change in indefinite reinvestment assertion | — | (30) | — | (30) |
| Change in valuation allowance-other | — | (5) | — | (5) |
| Other items | (3) | 11 | 1 | — |
| Income tax expense (benefit) | $6 | $(60) | $120 | $(105) |
Net Income Available to Noncontrolling Interests
Net income available to noncontrolling interests was $74 million for the three months ended September 30, 2018 compared to $78 million for the three months ended September 30, 2017. Net income available (loss attributable) to noncontrolling interests for the three months ended September 30, 2018 was comprised of $(9) million related to our Hospital Operations and other segment, $70 million related to our Ambulatory Care segment and $13 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $2 million was related to the minority interests in USPI.
Net income available to noncontrolling interests was $248 million for the nine months ended September 30, 2018 compared to $254 million for the nine months ended September 30, 2017. Net income available (loss attributable) to noncontrolling interests for the nine months ended September 30, 2018 was comprised of $(11) million related to our Hospital Operations and other segment, $209 million related to our Ambulatory Care segment and $50 million related to our Conifer segment. Of the portion related to our Ambulatory Care segment, $15 million was related to the minority interests in USPI.
ADDITIONAL SUPPLEMENTAL NON-GAAP DISCLOSURES
The financial information provided throughout this report, including our Condensed Consolidated Financial Statements and the notes thereto, has been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). However, we use certain non-GAAP financial measures defined below in communications with investors, analysts, rating agencies, banks and others to assist such parties in understanding the impact of various items on our financial statements, some of which are recurring or involve cash payments. We use this information in our analysis of the performance of our business, excluding items we do not consider relevant to the performance of our continuing operations. In addition, we use these measures to define certain performance targets under our compensation programs.
“Adjusted EBITDA” is a non-GAAP measure defined by the Company as net income available (loss attributable) to Tenet Healthcare Corporation common shareholders before (1) the cumulative effect of changes in accounting principle, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating expense, net, (7) interest expense, (8) litigation and investigation (costs) benefit, net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, and (12) income (loss) from divested operations and closed businesses (i.e., our health plan businesses). Litigation and investigation costs do not include ordinary course of business malpractice and other litigation and related expense.
The Company believes the foregoing non-GAAP measure is useful to investors and analysts because it presents additional information about the Company’s financial performance. Investors, analysts, Company management and the Company’s board of directors utilize this non-GAAP measure, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to peer companies, which utilize similar non-GAAP measures in their presentations. The Human Resources Committee of the Company’s board of directors also uses certain non-GAAP measures to evaluate management’s performance for the purpose of determining incentive compensation. The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to GAAP and other non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance. The non-GAAP Adjusted EBITDA measure the Company utilizes may not be comparable to similarly titled measures reported by other companies. Because this measure excludes many items that are included in our financial statements, it does not provide a complete measure of our operating performance. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.
The table below shows the reconciliation of Adjusted EBITDA to net income available (loss attributable) to Tenet Healthcare Corporation common shareholders (the most comparable GAAP term) for the three and nine months ended September 30, 2018 and 2017:
| Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 | |
|---|---|---|---|---|
| Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders | $(9) | $(367) | $116 | $(475) |
| Less: Net income available to noncontrolling interests | (74) | (78) | (248) | (254) |
| Income (loss) from discontinued operations, net of tax | — | (1) | 3 | (1) |
| Income (loss) from continuing operations | 65 | (288) | 361 | (220) |
| Income tax benefit (expense) | (6) | 60 | (120) | 105 |
| Loss from early extinguishment of debt | — | (138) | (2) | (164) |
| Other non-operating expense, net | — | (4) | (2) | (14) |
| Interest expense | (249) | (257) | (758) | (775) |
| Operating income | 320 | 51 | 1,243 | 628 |
| Litigation and investigation costs | (9) | (6) | (28) | (12) |
| Net gains (losses) on sales, consolidation and deconsolidation of facilities | (7) | 104 | 111 | 142 |
| Impairment and restructuring charges, and acquisition-related costs | (46) | (329) | (123) | (403) |
| Depreciation and amortization | (204) | (219) | (602) | (662) |
| Income (loss) from divested and closed businesses (i.e., the Company’s health plan businesses) | 9 | (6) | 9 | (41) |
| Adjusted EBITDA | $577 | $507 | $1,876 | $1,604 |
| Net operating revenues | $4,489 | $4,586 | $13,694 | $14,201 |
| Less: Net operating revenues from health plans | 8 | 10 | 14 | 100 |
| Adjusted net operating revenues | $4,481 | $4,576 | $13,680 | $14,101 |
| Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders as a % of net operating revenues | (0.2)% | (8.0)% | 0.8% | (3.3)% |
| Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin) | 12.9% | 11.1% | 13.7% | 11.4% |
LIQUIDITY AND CAPITAL RESOURCES
CASH REQUIREMENTS
There have been no material changes to our obligations to make future cash payments under contracts and under contingent commitments, such as standby letters of credit and minimum revenue guarantees, as disclosed in our Annual Report, except for the purchase of long-term debt, as discussed in Note 6 to our accompanying Condensed Consolidated Financial Statements.
As part of our long-term objective to manage our capital structure, we may from time to time seek to retire, purchase, redeem or refinance some of our outstanding debt or equity securities subject to prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. These actions are part of our strategy to manage our leverage and capital structure over time, which is dependent on our total amount of debt, our cash and our operating results. We continue to seek further initiatives to increase the efficiency of our balance sheet by generating incremental cash, including by means of the sale of underutilized or inefficient assets.
At September 30, 2018, using the last 12 months of Adjusted EBITDA, our ratio of total long-term debt, net of cash and cash equivalent balances, to Adjusted EBITDA was 5.70x, excluding nine months of California provider fee revenues related to 2017 because the program was not approved by CMS until December 2017. We anticipate this ratio will fluctuate from quarter to quarter based on earnings performance and other factors, including the use of our revolving credit facility as a source of liquidity and acquisitions that involve the assumption of long-term debt. We intend to manage this ratio by following our business plan, managing our cost structure, possible asset divestitures and through other changes in our capital structure, including, if appropriate, the issuance of equity or convertible securities. Our ability to achieve our leverage and capital structure objectives is subject to numerous risks and uncertainties, many of which are described in the Forward-Looking Statements and Risk Factors sections in Part I of our Annual Report.
Our capital expenditures primarily relate to the expansion and renovation of existing facilities (including amounts to comply with applicable laws and regulations), equipment and information systems additions and replacements, introduction of new medical technologies, design and construction of new buildings, and various other capital improvements, as well as commitments to make capital expenditures in connection with the acquisitions of businesses. Capital expenditures were $404 million and $492 million in the nine months ended September 30, 2018 and 2017, respectively. We anticipate that our capital expenditures for continuing operations for the year ending December 31, 2018 will total approximately $625 million to $675 million, including $117 million that was accrued as a liability at December 31, 2017. We have been engaged in a series of legal challenges over the Certificate of Need that the South Carolina Department of Health and Environmental Control initially granted to us in 2005 to construct a new 100-bed acute care hospital in Fort Mill, South Carolina. We are unable to predict when these challenges will be resolved or if they will ultimately be resolved in our favor; however, if we prevail, we expect that we will begin construction of the hospital soon after resolution. Once construction begins, the hospital is expected to take up to two years to complete at a cost of approximately $170 million over the construction period.
Interest payments, net of capitalized interest, were $652 million and $617 million in the nine months ended September 30, 2018 and 2017, respectively.
Income tax payments, net of tax refunds, were approximately $24 million in the nine months ended September 30, 2018 compared to $54 million in the nine months ended September 30, 2017.
SOURCES AND USES OF CASH
Our liquidity for the nine months ended September 30, 2018 was primarily derived from net cash provided by operating activities, cash on hand and borrowings under our revolving credit facility. We had approximately $500 million of cash and cash equivalents on hand at September 30, 2018 to fund our operations and capital expenditures, and our borrowing availability under our credit facility was $998 million based on our borrowing base calculation at September 30, 2018.
Our primary source of operating cash is the collection of accounts receivable. As such, our operating cash flow is impacted by levels of cash collections, as well as levels of implicit price concessions and bad debt, due to shifts in payer mix and other factors.
Net cash provided by operating activities was $799 million in the nine months ended September 30, 2018 compared to $709 million in the nine months ended September 30, 2017. Key factors contributing to the change between the 2018 and 2017 periods include the following:
- Increased net cash receipts of $152 million related to the California provider fee program;
- Additional interest payments of $35 million in the 2018 period primarily due to the six-month interest payment in January 2018 related to our 7.500% senior secured second lien notes due 2022, which were issued in December 2016; changes in the timing of certain interest payments as a result of our refinancing transactions in 2017 also impacted the year-over-year comparison;
- $25 million of additional payments in the 2018 period for restructuring charges, acquisition-related costs, and litigation costs and settlements;
- Lower income tax payments of $30 million in the 2018 period;
- Increased cash flows from our health plan businesses of approximately $100 million due to cash outflows in the 2017 period resulting from the sales and wind-down of these businesses in 2017, compared to negligible cash flows in the 2018 period; and
- The timing of other working capital items.
Net cash provided by investing activities was $120 million for the nine months ended September 30, 2018 compared to $227 million for the nine months ended September 30, 2017. The primary reason for the decrease was proceeds from sales of facilities and other assets of $498 million in the 2018 period when we completed the sale of our hospitals, physician practices and related assets in the Philadelphia area, the sale of MacNeal Hospital and other operations affiliated with the hospital in the Chicago area, and the sale of Des Peres Hospital in St. Louis compared to proceeds from sales of facilities and other assets of $826 million in the 2017 period when we completed the sale of our hospitals, physician practices and related assets in Houston, Texas. There was an increase in proceeds from sales of marketable securities, long-term investments and other assets of $145 million in the 2018 period compared to the 2017 period primarily due to the sales of our minority interests in four North Texas hospitals. Capital expenditures were $404 million and $492 million in the nine months ended September 30, 2018 and 2017, respectively.
Net cash used in financing activities was $1.030 billion and $1.223 billion for the nine months ended September 30, 2018 and 2017, respectively. The 2018 amount included our purchase of approximately $68 million aggregate principal amount of our 6.875% senior unsecured notes due 2031, approximately $28 million aggregate principal amount of our 6.750% senior unsecured notes due 2023, and approximately $22 million aggregate principal amount of our 7.000% senior unsecured notes due 2025. The 2018 amount also included $643 million related to purchases of noncontrolling interests, primarily our purchase of an additional 15% ownership interest in USPI and to settle the adjustment to the price we paid in 2017 based on actual 2017 financial results of USPI, compared to $722 million related to purchases of noncontrolling interests in the 2017 period, when we increased our ownership interest in USPI from approximately 56.3% to 80%. The 2017 amount also included our redemption of $250 million aggregate principal amount of our 8.000% senior unsecured notes due 2020 using cash on hand, as well as $912 million of payments to defease our floating rate senior secured notes due 2020, partially offset by $830 million proceeds from the issuance of our 4.625% senior secured notes due 2024. Additionally, the 2017 amount included our purchase of the land and improvements associated with our Palm Beach Gardens Medical Center, which we previously leased under a capital lease, by retiring the lease obligation for approximately $44 million.
We record our marketable equity securities and our marketable debt securities that are available-for-sale at fair market value. We have no investments that we expect will be negatively affected by the current economic conditions such that they will materially impact our financial condition, results of operations or cash flows.
DEBT INSTRUMENTS, GUARANTEES AND RELATED COVENANTS
*Senior Unsecured Note Purchases—*In August 2018, we purchased approximately $38 million aggregate principal amount of our 6.875% senior unsecured notes due 2031 for approximately $36 million, including approximately $1 million in accrued and unpaid interest through the dates of purchase. In May 2018, we purchased approximately $30 million aggregate principal amount of our 6.875% senior unsecured notes due 2031 for approximately $28 million. In March 2018, we purchased approximately $28 million aggregate principal amount of our 6.750% senior unsecured notes due 2023 and approximately $22 million aggregate principal amount of our 7.000% senior unsecured notes due 2025 for approximately $51 million, including approximately $1 million in accrued and unpaid interest through the dates of purchase. In connection with these purchases, we recorded losses from early extinguishment of debt of approximately $2 million in the nine months ended September 30, 2018, primarily related to the write-off of associated unamortized note discount and issuance costs, partially offset by the difference between the purchase price and the par value of the notes. These purchases were made under an authorization that our board of directors provided in the three months ended September 30, 2017 to purchase up to $150 million of debt in the open market. This authorization will expire on December 31, 2018. At September 30, 2018, there was approximately $32 million remaining under this authorization.
Credit Agreement. We have a senior secured revolving credit facility (as amended, the “Credit Agreement”) that provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. Obligations under the Credit Agreement, which has a scheduled maturity date of December 4, 2020, are guaranteed by substantially all of our domestic wholly owned hospital subsidiaries and are secured by a first-priority lien on the accounts receivable owned by us and the subsidiary guarantors. At September 30, 2018, we were in compliance with all covenants and conditions in our Credit Agreement. At September 30, 2018, we had no cash borrowings outstanding under the Credit Agreement, and we had approximately $2 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $998 million was available for borrowing under the Credit Agreement at September 30, 2018.
Letter of Credit Facility. We have a letter of credit facility (as amended, the “LC Facility”) that provides for the issuance of standby and documentary letters of credit, from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). The maturity date of the LC Facility is March 7, 2021. Obligations under the
LC Facility are guaranteed and secured by a first-priority pledge of the capital stock and other ownership interests of certain of our wholly owned domestic hospital subsidiaries on an equal ranking basis with our senior secured first lien notes. At September 30, 2018, we were in compliance with all covenants and conditions in our LC Facility. At September 30, 2018, we had approximately $96 million of standby letters of credit outstanding under the LC Facility.
For additional information regarding our long-term debt and capital lease obligations, see Note 6 to our accompanying Condensed Consolidated Financial Statements and Note 6 to the Consolidated Financial Statements included in our Annual Report.
LIQUIDITY
From time to time, we expect to engage in additional capital markets, bank credit and other financing activities depending on our needs and financing alternatives available at that time. We believe our existing debt agreements provide flexibility for future secured or unsecured borrowings.
Our cash on hand fluctuates day-to-day throughout the year based on the timing and levels of routine cash receipts and disbursements, including our book overdrafts, and required cash disbursements, such as interest and income tax payments. These fluctuations result in material intra-quarter net operating and investing uses of cash that have caused, and in the future could cause, us to use our Credit Agreement as a source of liquidity. We believe that existing cash and cash equivalents on hand, availability under our Credit Agreement, anticipated future cash provided by operating activities, and our investments in marketable securities of our captive insurance companies classified as noncurrent investments on our balance sheet should be adequate to meet our current cash needs. These sources of liquidity, in combination with any potential future debt incurrence, should also be adequate to finance planned capital expenditures, payments on the current portion of our long-term debt, payments to joint venture partners, including those related to put and call arrangements, and other presently known operating needs.
Long-term liquidity for debt service and other purposes will be dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings. However, our cash requirements could be materially affected by the use of cash in acquisitions of businesses, repurchases of securities, the exercise of put rights or other exit options by our joint venture partners, and contractual commitments to fund capital expenditures in, or intercompany borrowings to, businesses we own. In addition, liquidity could be adversely affected by a deterioration in our results of operations, including our ability to generate cash from operations, as well as by the various risks and uncertainties discussed in this section and other sections of this report and in our Annual Report, including any costs associated with legal proceedings and government investigations.
We do not rely on commercial paper or other short-term financing arrangements nor do we enter into repurchase agreements or other short-term financing arrangements not otherwise reported in our period-end balance sheets. In addition, we do not have significant exposure to floating interest rates given that all of our current long-term indebtedness has fixed rates of interest.
OFF-BALANCE SHEET ARRANGEMENTS
We have no off-balance sheet arrangements that may have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for $155 million of standby letters of credit outstanding and guarantees at September 30, 2018.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements in conformity with GAAP, we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular circumstances in which we operate. Actual results may vary from those estimates.
We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different outcomes under different conditions or when using different assumptions.
Our critical accounting estimates have not changed from the description provided in our Annual Report, except for the changes related to the implementation of ASU 2014-09. See Note 1 to our accompanying Condensed Consolidated Financial Statements for a description of our revised policies for revenue recognition.
Market risk
As filed, 1,632 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following table presents information about certain of our market-sensitive financial instruments at September 30, 2018. The fair values were determined based on quoted market prices for the same or similar instruments. The average effective interest rates presented are based on the rate in effect at the reporting date. The effects of unamortized premiums, discounts and issue costs are excluded from the table.
(Dollars in Millions)
| Maturity Date, Years Ending December 31, 2018 | 2019 | 2020 | 2021 | 2022 | Thereafter | Total | Fair Value | |
|---|---|---|---|---|---|---|---|---|
| Fixed rate long-term debt | $111 | $613 | $2,686 | $1,950 | $3,578 | $6,106 | $15,044 | $15,186 |
| Average effective interest rates | 5.8% | 5.7% | 6.2% | 4.7% | 8.5% | 6.1% | 6.5% |
At September 30, 2018, we had long-term, market-sensitive investments held by our captive insurance subsidiaries. Our market risk associated with our investments in debt securities classified as non-current assets is substantially mitigated by the long-term nature and type of the investments in the portfolio.
We have no affiliation with partnerships, trusts or other entities (sometimes referred to as “special-purpose” or “variable-interest” entities) whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements by us. As a result, we have no exposure to the financing, liquidity, market or credit risks associated with such entities.
We do not hold or issue derivative instruments for trading purposes and are not a party to any instruments with leverage or prepayment features.
Controls and procedures
As filed, 1,064 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. The evaluation was performed under the supervision and with the participation of management, including our chief executive officer and chief financial officer. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the Exchange Act and the SEC rules thereunder.
There were no changes in our internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $4.49bn | us-gaap:Revenues |
| Revenue | 9 months2018-01-01 to 2018-09-30 | $13.69bn | us-gaap:Revenues |
| Operating income | 3 months2018-07-01 to 2018-09-30 | $320.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | $1.24bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-07-01 to 2018-09-30 | $249.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2018-01-01 to 2018-09-30 | $758.0m | us-gaap:InterestExpense |
| Income tax | 3 months2018-07-01 to 2018-09-30 | $6.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-01-01 to 2018-09-30 | $120.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-07-01 to 2018-09-30 | $65.0m | us-gaap:ProfitLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | $364.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | $1.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-07-01 to 2018-09-30 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2018-01-01 to 2018-09-30 | $1.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-07-01 to 2018-09-30 | 102,402,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2018-01-01 to 2018-09-30 | 103,802,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | $799.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $404.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $500.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $4.49bn | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $22.27bn | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $4.22bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $20.16bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-09-30 | −$108.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000070318-18-000039. Last ingested by Listed: Nov 15, 2026, 02:42 ET. Listed shows no prices and gives no investment advice.